New drugs being developed and those in production have to undergo a lot of trials, data collection, and research before they are available to the public. Clinical trials are used to design such drugs through testing and studies conducted on patients enrolled in clinical trials.
Optimization of this phase ensures the data collected is substantial and useful for management and the creation of working solutions. Clinical research takes a long period to conduct and complete and this has huge cost implications. The technology for clinical trial optimization still has a long way before it becomes part of the system.
Enrolment and analysis of cohorts play a huge role in collecting samples and targeting the right drug for clinical development. Accelerating clinical trials with a strategic decentralized approach could improve the results and data collected.
Flexibility of Protocols
Before a clinical trial begins, traditionally all metrics were set in stone. The criteria for selecting a cohort were predetermined, the doses each participant in the study would receive, and the outcomes expected from each trial phase. The time to run the trial was also set. Any deviation from this set of rules was either disregarded or simply not analysed further. Optimisation of this analysis phase could change the trial method.
Adapting the protocols to the incoming data changes the methodology and approach as the trial unfolds. Eliminating what is not working and improving on what services are bringing results could change the trial phase. The duration of the trial has a great impact on the data collected and its operability. The more time spent on following the outcomes that provide results increases the chances of designing a better drug.
Cohort selection impacts the data collected, focussing on the patients that show affinity to the drug and respond to treatment and enriching this group could be of higher significance.
Speed and Cost
The longer a clinical trial lasts, the higher the cost of running the analysis. It is important to use a minimal amount of time and collect the most relevant amount of data. Focusing on data collected in each phase of the study and following the improved capabilities in each result could be the difference in whether the drug works or not.
Simulation would not make the drug effective if it is not working. Accelerated research could provide answers and leads according to data collected. Research on ineffective samples could be stopped earlier and resources focussed on what needs to be improved.
AI in Clinical Trials
As the world moves toward artificial intelligence in all aspects of life, pharmaceutical organizations try to incorporate its use into drug design. AI offers speed in many factors associated with clinical studies. The selection of cohorts and patients to be enrolled can be optimised to include similar cases to be tested. The recruitment of patients by managing data is faster and more precise.
Outcomes of each study can be analysed faster and result combined efficiently for the study metrics. Reaching target enrolment rates and observation of regions with prevalent conditions that are optimal for the research become easier with the use of AI. By searching medical records and detecting patient subgroups the target study groups become more efficient and data more conclusive.
Alerts for medical staff and patients for enrolment in studies and analysis are increased and easier management of the data collected. Matching certain aspects of the study and analysis phases could accelerate production and reduce costs.
However, managing such a task is not easy. The inherent bias in such data and the mismanagement of universal data could fail the effectiveness of AI. Resolving issues in the available data could make the use of Artificial Intelligence much more successful.
Clinical trial optimization podcasts have started gaining popularity with the number of people planning to join trials and those already grouped in studies. Potential participants get knowledge of the products being tested and gain insight as to how the trial will be conducted.
Optimizing the phases of a study has a higher potential of gaining an understanding as to which product could potentially be more useful. A drug could be really good but the trial period may not provide enough data to satisfy the metrics that have been put in place.
Max Page is a visionary and a leading expert in the realm of Android app development, particularly at the intersection of AI and IoT technologies. As the founder and principal author of Agiledroid.com, Max has established himself as a thought leader in harnessing the power of artificial intelligence to revolutionize Android applications.
